

As you may be aware, Insys recently entered into a civil, criminal, and administrative settlement with the United States in connection with Insys's promotion of SUBSYS®. This letter provides you with additional information about the global settlement, explains Insys's commitments going forward, and provides you with access to information about those commitments.

The Government alleges that Insys engaged in several types of unlawful and improper conduct relating to the promotion of SUBSYS®. To address criminal liability, Insys agreed to enter a Deferred Prosecution Agreement and pay \$30 million in criminal fines and forfeiture. A subsidiary of Insys agreed to plead guilty to criminal charges. In addition, to resolve liability under the Federal False Claims Act (including the alleged payment of kickbacks), Insys agreed to enter a civil settlement and pay \$195 million. More information about the criminal and civil resolutions may be found at the following:

<https://www.justice.gov/usao-ma/pr/insys-therapeutics-agrees-enter-225-million-global-resolution-criminal-and-civil> , <https://www.justice.gov/opa/pr/opioid-manufacturer-insys-therapeutics-agrees-enter-225-million-global-resolution-criminal> , and <https://www.insysrx.com> .

As part of the global settlement, Insys also entered into a corporate integrity agreement and conditional exclusion release with the Office of Inspector General of the U.S. Department of Health and Human Services. That agreement is available at <https://oig.hhs.gov/compliance/corporate-integrity-agreements/cia-documents.asp> . Under the agreement, Insys agreed to undertake certain obligations designed to promote compliance with Federal health care program and FDA requirements. We also agreed to notify healthcare providers about the settlement and inform them that they can report any questionable practices by Insys's representatives to Insys's Compliance organization or the FDA using the information set out below.

Please call Insys at 480-656-9020 or visit us at <https://www.insysrx.com/contact/general-contact> if you have questions about the settlement referenced above. Please call Insys at 855-433-9921 or visit us at ethicspoint@navexglobal.com to report any instances in which you believe that an Insys representative inappropriately promoted a product or engaged in other questionable conduct. Alternatively, you may report any improper conduct associated with prescription drug marketing committed by an Insys Representative to the FDA's Office of Prescription Drug Promotion at 301-796-1200. You should direct medical questions or concerns about Insys products to 877-978-2797.



Andrew G. Long
Chief Executive Officer